- Home
- India
- Top Stories
- Covovax trials begin in India, hope to launch it by Sept 2021: SII CEO Adar Poonawalla
Covovax trials begin in India, hope to launch it by Sept 2021: SII CEO Adar Poonawalla
Serum Institute of India CEO Adar Poonawalla on Saturday said clinical trials of COVID-19 vaccine Covovax have begun in India and the company hopes to launch it by September this year.
- FB
- TW
- Linkdin
 "<p>Serum Institute of India (SII) CEO Adar Poonawalla on Saturday said clinical trials of Covid-19 vaccine Covovax have begun in India and the company hopes to launch it by September this year.</p>")
<p>Serum Institute of India (SII) CEO Adar Poonawalla on Saturday said clinical trials of Covid-19 vaccine Covovax have begun in India and the company hopes to launch it by September this year.</p>
Serum Institute of India (SII) CEO Adar Poonawalla on Saturday said clinical trials of Covid-19 vaccine Covovax have begun in India and the company hopes to launch it by September this year.
<p>In August 2020, American vaccine company Novavax, Inc had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its Covid-19 vaccine candidate, in low and middle-income countries and India.</p>
In August 2020, American vaccine company Novavax, Inc had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its Covid-19 vaccine candidate, in low and middle-income countries and India.
<p>"Covovax trials finally begin in India; the vaccine is made through a partnership with @Novavax and @SerumInstIndia. It has been tested against African and UK variants of #Covid19 and has an overall efficacy of 89%. Hope to launch by September 2021!," Poonawalla said in a tweet.</p> <p> </p>
"Covovax trials finally begin in India; the vaccine is made through a partnership with @Novavax and @SerumInstIndia. It has been tested against African and UK variants of #Covid19 and has an overall efficacy of 89%. Hope to launch by September 2021!," Poonawalla said in a tweet.
